Fuyuan Pharmaceuticals (601089.SH): Clinical trial approval for Lidocaine and Pramoxine aerosol.

Wisdom Financial News APP News, Fuyuan Pharmaceutical (601089.SH) announced that its wholly-owned subsidiary Fuyuan Pharma Co., Ltd. (referred to as "Fuyuan Pharma") has received the "Drug Clinical Trial Approval Notice" of lidocaine prilocaine aerosol approved and issued by the National Medical Products Administration. Fuyuan Pharma Co., Ltd. applied for clinical trials of lidocaine prilocaine aerosol, indicated for the treatment of primary premature ejaculation in adult males. The route of administration is local, and the registration classification belongs to Class 3 chemical drugs.